Introduction
Prostate cancer is the most frequent malignant tumor among males in developed countries and the second leading cause for cancer-related death (Hsing et al., 2000) . Androgen withdrawal is an effective therapy for patients with advanced prostate cancer, but progression to hormone independence occurs ultimately in almost all patients after a few months or years (Petrylak et al., 2004) . Although numerous non-hormonal agents have been evaluated in patients with hormone-refractory prostate cancer, these agents have limited antitumor activity with modest or no effect on survival (Petrylak et al., 2004) . Therefore, identification and selected inhibition of molecular targets that mediate progression of prostate cancer are highly warranted.
The molecular mechanisms underlying progression to metastatic and hormone-refractory prostate cancer are poorly understood. High-level amplifications can pinpoint to genomic sites containing activated oncogenes with major biologic and therapeutic importance (Albertson et al., 2003) . We have recently identified an amplification at 10q22 prevailing in approximately 15% of hormone-refractory prostate cancers and in the hormone-insensitive prostate cancer cell line PC-3 (Bernardino et al., 1997; El Gedaily et al., 2001) . Amplification of 10q22 appears to be absent or exceedingly rare in other tumor types, suggesting that this chromosomal region harbors genes that specifically drive progression of prostate cancer (Knuutila et al., 2000) .
The KCNMA1 gene is located at 10q22 and encodes the pore-forming a-subunit of the large-conductance Ca 2 þ -activated K þ channel (also known as BK-channel, Maxi K þ channel, slowpoke) that can tetramerize to a fully active BK channel (Tseng-Crank et al., 1994; Quirk and Reinhart, 2001) . In mammalian tissues, KCNMA1 is almost ubiquitously expressed along with four regulatory b-subunits KCNMB1-4 (Rebhan et al., 1997; Orio et al., 2002) .
Numerous functions have been attributed to BK channels, including modulation of smooth muscle tone of blood vessels and uterus (Zhou et al., 2000; , synaptic neurotransmitter release (Robitaille and Charlton, 1992) and epithelial transport (Kunzelmann and Mall, 2002) . Most recently, attention has been drawn to the BK channel as a critical player in blood pressure regulation and in the neurotropic effect of ethanol (Davies et al., 2003) . Hence, potassium channelmodulating agents have been suggested as therapeutic agents in neurological and cardiovascular disorders (Calderone, 2002) .
Apart from this, growing evidence exists that K þ channels may also be involved in oncogenesis. For example, BK channel activation has been shown to drive tumor cell proliferation in astrocytoma (Basrai et al., 2002) . Moreover, a previous report has suggested a role of potassium channels for the proliferation of prostate cancer (Van Coppenolle et al., 2004) . Here, we demonstrate that KCNMA1 is amplified in a subset of late-stage prostate cancers in vivo, and that BK channel activity alters growth of human prostate cancer in vitro.
Results

KCNMA1 amplification and overexpression of BK channels
Human prostate cell lines were analysed for KCNMA1 amplification by fluorescence in situ hybridization (FISH). Amplification, defined as a signal ratio of the KCNMA1 gene/centromere of chromosome 10X2 and at least five gene signals, was present in the hormoneinsensitive prostate cancer cell line PC-3 but not in the hormone-sensitive prostate cell lines BPH-1 or LNCaP (Figure 1 ). To explore whether this amplification also prevails in vivo, a series of 298 formalin-fixed and paraffin-embedded human prostate specimens was analysed on a tissue microarray. We found amplification in 16.0% of 119 advanced prostate cancers including untreated locally aggressive tumors (20%), distant metastases (13%) and local recurrences (22%) from hormone-refractory tumors but not in benign prostatic hyperplasia, precursor lesions (high-grade prostatic intraepithelial neoplasia) and clinically localized prostate cancers (Table 1) . These results suggest that amplification of KCNMA1 is associated with progression to late-stage, metastatic and hormone-refractory human prostate cancer. The FISH results of KCNMA1 were compared with PLAU, a previously suggested candidate target gene at 10q22 (Helenius et al., 2001) . Comparable to KCNMA1, PLAU amplification was present in PC-3 but not in BPH-1 and LNCaP. Analysis of 133 specimens revealed a similar prevalence and distribution of PLAU amplification among the different tumor stages as KCNMA1 amplification (Table 1) . PLAU amplification was absent in specimens of benign prostatic hyperplasia and in clinically localized prostate cancers but present in untreated locally aggressive tumors (14%), lymph node metastases (13%), distant metastases (13%) and in hormone-refractory local recurrences (12%). The difference in the prevalence of amplification of these two genes in the different subgroups of tumors stages was statistically not significant.
To study whether amplification of KCNMA1 results in overexpression, we compared the mRNA levels of KCNMA1 in the amplified PC-3 cell line with the nonamplified cell lines BPH-1 and LNCaP using semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). Expression of KCNMA1 was significantly 
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M Bloch et al higher in PC-3 as compared to LNCaP and BPH-1, suggesting that KCNMA1 amplification drives overexpression of the channel protein ( Figure 2a ). In fact, increased levels of KCNMA1 protein in PC-3 as opposed to the control cell lines were documented by immunofluorescence ( Figure 2b ). The fluorescence intensity (mean of optical density7error of the mean) was significantly higher in PC-3 (27 75972061; 10 cells) than in LNCaP (10 8067259; 12 cells) and BPH-1 (317719.2; 13 cells; Po0.0001; stains were repeated twice). Immunofluorescence on human prostatic tissue revealed strong BK expression in smooth muscle cells of the fibromuscular stroma. This is in line with previous reports showing strong expression in smooth muscle of other sites such as blood vessels and colonic wall (McCobb et al., 1995; Sausbier et al., 2006) . BK expression also prevailed in all six prostatic adenocarcinomas and the intensity varied from weak to moderate (Figure 3) . None of the tumors met the criteria for KCNMA1 gene amplification by FISH. One tumor had increased gene copy number of KCNMA1 (5-7 gene signals and 4-5 reference signals) and showed moderate BK expression (Figure 3a) . However, expression at a similar level was also found in tumors with a normal gene copy number (Figure 3f ). Benign prostatic glands showed weak expression of BK.
BK channel currents in prostate cancer cells
The prostate cell lines PC-3 and BPH-1 were used as in vitro models to study the influence of KCNMA1 currents for cell proliferation. Functional expression of BK channels in PC-3 and BPH-1 cells was examined in patch clamp experiments. Iberiotoxin (IBTX), a wellknown and highly specific inhibitor of the BK channel (Galvez et al., 1990) , reversibly inhibited whole-cell current (I m ) and conductance (G m ) in PC-3 (Figure 4a and b). Inhibition of whole-cell currents was paralleled by a depolarization of the membrane voltage (V m ).
Other than in PC-3 cells, IBTX had only minor effects Abbreviations: BPH, benign prostatic hyperplasia; LN metastases, pelvic or paraortal lymph node metastases; PIN, prostatic intraepithelial hyperplasia; T1a/b, incidentally detected prostate cancer in transurethral resection for presumed BPH; T2, clinically organ confined prostate cancer treated by radical prostatectomy; T3/4, clinically non-organ confined, locally advanced prostate cancer treated with palliative transurethral resection. FISH analysis on a prostate-specific tissue microarray (TMA). The BAC RP11-428P16 was used as KCNMA1-specific probe, the BAC RP11-417O11was used as PLAU-specific probe and the centromeric probe for chromosome 10 as a reference. The total number of specimens evaluable for KCNMA1 and PLAU was 298 and 133, respectively. Amplification was defined as a ratio between gene and reference of X2 and at least five gene signals. Figure 4c ). Whole-cell patch clamp experiments were performed in the same media as proliferation assays. Under these 'proliferative' conditions, the membrane voltage (V m ) of both BPH-1 (À1871.8 mV, n ¼ 13) and PC-3 (À2372.0 mV, n ¼ 17) cells was depolarized. Although depolarization of V m allows for activation of BK channels, IBTX inhibited membrane conductance was only found in PC-3 cells but not in BPH-1 cells. In Ringer solution both PC-3 and BPH-1 cells were hyperpolarized to À5872.1 mV (n ¼ 14) and À5973.8 mV (n ¼ 17) and IBTX-sensitive membrane conductance was reduced (data not shown). Other Ca 2 þ -activated K þ channels such as small and intermediate conductance channels showed negligible contribution to the whole-cell conductance of PC-3 and BPH-1 cells (data not shown).
The whole-cell K þ conductance could not be augmented by the BK channel activator 17b-estradiol in PC-3 (Valverde et al., 1999) , but was further enhanced along with a hyperpolarization of the membrane voltage in BPH-1 (Figure 4d) . The results suggest a high activity of BK channels in PC-3 that cannot be further increased by 17b-estradiol. These findings were supported by inside/out excision of membrane patches from PC-3 cells into a bath solution containing high Ca 2 þ concentration.
Under these conditions, large conductance BK channels were regularly detected in PC-3 (Figure 4e ), but only occasionally found in membrane patches of BPH-1. The open probability (P o ) of the single channel was enhanced at depolarized membrane voltages, and the single channel conductance was about 220 pS at symmetrical K þ concentrations of 150 mM, which is characteristic for BK channels.
Impact of BK channel activity on proliferation of prostate cancer cells
We examined the response of PC-3, BPH-1 and LNCaP to modulation of BK channel activity ( Figure 5 ). The basal growth rate was higher in PC-3 than in BPH-1 and was significantly inhibited by the BK channel inhibitor IBTX (P ¼ 0.015). This indicates a central role of BK channels for proliferation of PC-3 under normal growth conditions (Figure 5a ). In contrast, there was no significant effect of IBTX on the growth of BPH-1 and LNCaP (P>0.05, Figure 5b and c). 17b-estradiol significantly stimulated growth of BPH-1 (P ¼ 0.0021) and LNCaP (P ¼ 0.0039) but not PC-3 cells (Figure 5a-c) . The growth effect of 17b-estradiol was abolished by IBTX both in BPH-1 and LNCaP. This finding suggests that the steroid exerts its stimulatory effects on cell proliferation in BPH-1 and LNCaP through activation 
KCNMA1 amplification in prostate cancer
M Bloch et al of BK channels. In contrast, rapidly growing PC-3 cells proliferate independently of 17b-estradiol, as the abundantly expressed BK channels operate already at high activity. The role of BK channels for proliferation of prostate cancer cells was further substantiated by gene-specific mRNA silencing using RNA interference (RNA i ). Four different types of anti-KCNMA1 small interference RNA molecules (siRNA K1-K4) were transfected into PC-3 cells, which all significantly reduced KCNMA1 mRNA expression and cell proliferation. The most potent KCNMA1 siRNA (K2) inhibited mRNA expression ( Figure 6a ) and cell proliferation (Figure 6b ) by 80-90%, when compared to non-transfected cells (c-si) or cells transfected with scrambled sequence siRNA (scr). Expression of KCNMA1 protein was largely reduced in siRNA K2-treated cells, when compared to non-transfected cells or cells transfected with scrambled sequence siRNA (Figure 6c) . In whole-cell patch clamp experiments, inhibition of the membrane conductance and depolarization of the membrane voltage by IBTX was significantly reduced in RNA i -treated cells (Figure 7a ). The BK-inhibitor paxillin rather than IBTX was used for analysis of excised inside out membrane patches as paxillin is applicable to the cytosolic side of the membrane. Analysis of excised inside out membrane patches of RNA i -treated cells revealed largely attenuated BK channel activity (nP o ) and a reduced effect of the BK channel blocker paxillin (Figure 7b) . Inhibition of BK channel activity by paxillin was much reduced in RNA i -treated PC-3 cells and was not detectable in BPH-1 cells (Figure 7c ). Taken together, the present data indicate a crucial role of KCNMA1 for proliferation of advanced and hormone-refractory prostate cancer cells. 
. N(t): number of cells at time t, N 0 ¼ number of cells at time 0, t in days.
Discussion
There is mounting evidence that K þ channels play a crucial role in oncogenesis, and their potential as therapeutic targets in cancer has been recognized (Pardo et al., 1999; Pei et al., 2003; Conti, 2004; Wang, 2004) . Here, we demonstrate that the large-conductance Ca 2 þ -activated potassium channel (KCNMA1) is amplified at 10q22 in 16% of late-stage, metastatic and hormonerefractory human prostate cancers. In the cell line PC-3, amplification of KCNMA1 is associated with overexpression of mRNA and protein, and a high density of BK channels in the cellular membrane as opposed to non-amplified cell lines. Importantly, growth inhibition by specific blockade of KCNMA1 activity using IBTX and RNA i in the amplified prostate cancer cell line PC-3 strongly argues for an oncogenic effect of KCNMA1 amplification and functional overexpression. Expression of BK channel protein is not restricted to cell lines in vitro but also present in human prostate cancers in vivo.
As well-detectable BK expression was found in tumors without KCNMA1 amplification, factors other than increased gene dosage must also be involved in the regulation of BK expression in prostate cancer.
The oncogenic role of KCNMA1 found in this study is in line with the previously reported growth inhibition of human astrocytoma by IBTX (Basrai et al., 2002; Weaver et al., 2004) . Interestingly, the intermediate conductance K
þ channel (IK) rather than KCNMA1 has been proposed to be important for PC-3 and LNCaP cells by Parihar et al. (2003) . Parihar et al. performed the efflux experiments under non-proliferative conditions, that is, in Ringer solution rather than in growth medium. In Ringer solution, however, the cells were hyperpolarized and thus BK channels and other voltage-gated K þ channels show little activity (Pardo, 2004; O'Grady and Lee, 2005) . The present data suggest that analysis of ion channels relevant to proliferation 
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M Bloch et al should be conducted under proliferative conditions, that is, in the presence of serum-containing culture media. Serum and glucocorticoid-inducible kinase, phosphoinositide-3 kinase and the mitogen-activated protein kinase pathway are activated by serum and have been shown to stimulate BK channels (Henke et al., 2004; O'Malley and Harvey, 2004) . The role of estrogens in prostate cancer is controversial and is also challenged by the present results. Despite the traditional use of estrogens for the treatment of prostate cancer, it is now known that estrogens can also induce neoplastic transformation in the prostate (Ho, 2004) . In addition, 17b-estradiol directly activates BK channels by binding to the b1-regulatory subunit, as shown in vascular smooth muscle cells (Valverde et al., 1999) . The present data provide evidence that 17b-estradiol stimulates growth of prostate cells through activation of BK channels. This growth stimulation by 17b-estradiol was pronounced in BPH-1 and LNCaP, but was absent in PC-3 cells. Missing activation of BK and lack of stimulation of cell proliferation by 17b-estradiol in PC-3 cells suggests that BK channels operate at maximal activity in these cells owing to overexpression driven by amplification. Interestingly, it has recently been shown that a proliferative effect of 17b-estradiol in the breast cancer cell line MCF-7 is also mediated by BK channels independently of estrogen receptor (Coiret et al., 2005) . PC-3 and BPH-1 are known to express estrogen receptor alpha and beta, whereas LNCaP only expresses the estrogen receptor beta (Lau et al., 2000) . Thus, 17b-estradiol might stimulate growth of BPH-1 and LNCaP by binding to the estrogen receptors. Alternatively, one could hypothesize that the growth effect of 17b-estradiol in LNCaP is due to altered ligand binding of the mutated androgen receptor (Veldscholte et al., 1992) . However, the prevention of the growth stimulation of estradiol by IBTX suggests that the BK channel activity plays a central role in this growth stimulation. This is also in accordance with the previously shown direct activation of BK channels by 17b-estradiol (Valverde et al., 1999) . Taken together, activation of BK channel might be a major target of 17b-estradiol in prostate cancer in the absence of KCNMA1 amplification and overexpression. However, it is likely that BK channels are modulated by a complex network of different molecules and molecular pathways (O'Malley and Harvey, 2004; Olsen et al., 2005) .
There is increasing evidence that gene amplification leads to growth advantage of tumor cells, as a set of multiple genes rather than a single gene is overexpressed (Reiter et al., 2000; Kauraniemi et al., 2001) . Along this line the urokinase-type plasminogen activator gene (uPA; syn. PLAU) has previously been suggested as amplification target at 10q22 in human prostate cancer (Helenius et al., 2001; Helenius et al., 2006) . As expected, PLAU amplification preferentially occurred in advanced prostate cancer at a similar prevalence as amplification of KCNMA1 in our study. Prosaposin (PSAP) at 10q22, which has growth-and invasionpromoting activities, is another gene that has recently been found to be amplified in PC-3 and a few prostate cancer xenografts and lymph node metastases by single nucleotide polymorphism array and quantitative real-time PCR analysis (Koochekpour et al., 2005) . Notably, PLAU stimulates Ca 2 þ -activated K þ channels in the human promyelocytic cell line U937 (Christow et al., 1999) , suggesting synergistic effects of coamplification of KCNMA1 and PLAU. This challenges new promising studies on the interaction between KCNMA1 and other genes within the amplified chromosomal region at 10q22.
In summary, the data presented in this study unmask KCNMA1 as an amplified target gene at 10q22 that confers growth advantage to prostate cancer cells. Thus, BK channel may be a suitable pharmacological target in patients with late-stage prostate cancer that show amplification and overexpression of KCNMA1.
Materials and methods
FISH probes
The bacterial artificial chromosome (BAC) RP11-428p16, which contains major parts of the KCNMA1 gene sequence, and the BAC RP11-417o11, which contains the whole genomic sequence of PLAU, were obtained from the Wellcome Trust Sanger Institute (Cambridge, UK). Growth conditions and DNA extraction were as recommended by the supplier. One microgram of purified plasmid DNA was labeled using a modified Bio Nick kit (Invitrogen, Carlsbad, CA, USA). The nucleotide solution of the nick kit was replaced by 0.2 mM each dCTP, dGTP, dTTP, 0.1 mM dATP, 500 mM Tris-HCl (pH 7.8), 50 mM MgCl2, 100 mM-mercaptoethanol, 100 mg/ml nuclease-free bovine serum albumin (BSA), 1 ml Digoxigenin (Roche Diagnostics, Basel, CH), and 1 ml DNA Polymerase 1 (Invitrogen) was added. Nick translation was performed at 161C for 90 min. The labeled FISH probes were purified by precipitation and re-dissolved in 50 ml H 2 O.
Clinical specimens
The 298 formalin-fixed and paraffin-embedded clinical specimens on the prostate tissue microarray were from the archive of the Institute for Pathology, University Hospital Basel, Switzerland. The tissue microarray was constructed as described previously (Kononen et al., 1998) . The size of each tissue spot was 0.6 mm. In addition, sections from eight frozen prostate tissue specimens were used for immunofluorescence. They were from four patients with hormone-refractory local recurrences treated by transurethral resection, two patients with clinically organ-confined disease treated by radical prostatectomy and from two patients with benign prostatic hyperplasia treated by transurethral resections. Specimens were kept anonymous, and the experiments were according to the guidelines of the ethical committee of the University of Basel.
Fluorescence in situ hybridization Paraffin removal (3 Â 5 min in Xylene followed by 2 Â 2 min ethanol 95% and air-drying) and enzymatic tissue pretreatment (Vysis pretreatment solution, 801C, 15 min) of tissue sections mounted on glass slides were performed in a VP2000 Processor device (Vysis, Downers Grove, IL, USA). Slides were rinsed in water for 2 min, incubated in protease K solution (Vysis) at 371C for 150 min and rinsed in water again. Subsequently, slides were dehydrated in an ascending ethanol series (70, 80, 95%) and air-dried. Then, a premixed hybridization cocktail containing 0.5 ml centromere 10 probe KCNMA1 amplification in prostate cancer M Bloch et al (CEP 10 Spectrum orange labeled; Vysis), 1.5 ml KCNMA1 probe (digoxigenin labeled), 1 ml Cot DNA (Invitrogen) and 7 ml hybridization buffer (Vysis) was added to each slide. For probe and target DNA denaturation, slides were heated to 721C for 10 min. Probes were allowed to hybridize overnight at 371C in a humidified chamber. The next day, slides were washed in 2 Â standard sodium citrate, 0.3%NP40, ph 7-7.5 at 721C for 2 min. The KCNMA1 probe was detected using the Dig detection kit (Roche Diagnostics). Amplification was defined as a signal ratio of gene probe/centromere 10X2 and at least five gene signals.
Cell lines and cell culture
We used the cell lines PC-3, LNCaP and BPH-1. PC-3 was originally established from a lumbar vertebral metastasis of a 62-year-old Caucasian man after treatment with diethylstilbestrol and bilateral orchiectomy (Kaighn et al., 1979) . LNCaP cells were isolated from a needle aspiration biopsy of the left supraclavicular lymph node metastasis of a 50-year-old Caucasian man (Horoszewicz et al., 1980) . BPH-1 originates from a 68-year-old patient with transurethral resection of the prostate for benign prostatic hyperplasia. The donor had not undergone hormonal therapy and did not have malignant disease. The cells were immortalized with a virus carrying the SV40T antigen and selected for resistance to geneticin. This cell line does not express androgen receptor and prostate specific antigen (Hayward et al., 1995) .
For the growth assays, 6 Â 25 000 cells were plated on a sixwell plate (Falcon, Becton-Dickinson, Franklin Lakes, NJ, USA). PC-3 and BPH-1 were grown in 3 ml OPTI-MEM (Invitrogen) þ 10% fetal calf serum (FCS, BioConcept, Allschwil, CH). After 1 day, the medium was changed to OPTI-MEM þ 1% FCS. At day 2, the medium was changed to OPTI-MEM þ 0.4% Albumax (Invitrogen) containing IBTX (Sigma, Fluka Production GmbH, St Louis, MO, USA) or 17 b-estradiol (Sigma, Fluka Production GmbH). IBTX was diluted in phosphate-buffered saline (PBS) to a final concentration of 20 nM. 17 b-estradiol was diluted in 70% ethanol to a final concentration of 1 nM. In contrast to PC-3 and BPH-1, LNCaP did not grow in Optimem þ 0.4% Albumax. Thus, the effects of estradiol and IBTX on growth of LNCaP were assayed in Optimem þ 5% FCS þ 0.2% Albumax. This medium contains reduced serum and still allows growth of LNCaP. After two days of growth, cell numbers were counted using a Neubauer Chamber. The growth rate k was calculated as N(t) ¼ N 0 * e kt , t ¼ time in days.
Western blot and immunofluorescence
Cells were lysed in sample buffer containing 1% sodium dodecyl sulfate (SDS) and 100 mmol/l dichlorodiphenyltrichloroethane. Protein concentrations were determined according to a modified Laury method. Lysates of PC-3 cells were resolved by 7% SDS-PAGE, transferred to Hybond-P (Amersham Pharmacia Biotech, Freiburg, BRD) and incubated with anti-KCNMA1 polyclonal antibody (generous gift by Professor Dr P Ruth, Institute of Pharmacy, University of Tu¨bingen, Germany). Proteins were visualized using a sheep anti rabbit immunoglobulin G, conjugated to horse radish peroxidase and ECL Advance Detection Kit (Amersham Pharmacia Biotech). For immunocytochemistry, PC-3, BPH-1 and LNCaP cells were grown on glass cover slips, washed three times in PBS and fixed in methanol at À201C. After washing in PBS, cells were incubated for 10 min in blocking buffer containing 10% BSA and 10% fish skin gelatine (both from Sigma). Cells were incubated overnight at 41C in blocking solution, containing the primary antibody (1:1000 dilution). Subsequently, cells were washed in PBS and incubated with the fluorescein isothiocynate (FITC)-linked secondary antibody for 1 h at 371C. Tissues were counter stained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (DAPI) solution (Sigma) and embedded in Mowiol (Sigma). Immunofluorescence was detected using an Axiovert 200 microscope and MetaFluor imaging software. Immunofluorescence on frozen tissue sections was performed as described previously (Sausbier et al., 2006) .
RNA interference (RNA i )
Transfection was performed following the siRNA transfection protocol for Lipofectamine 2000 (Qiagen, KJ Venlo, NL, USA). Briefly, 50 000 cells were plated in six-well plates (Falcon, Becton-Dickinson) one day before transfection. The transfection was performed in OPTI-MEM (Invitrogen) for 4 h. The transfection mixture contained 5 ml of siRNA and Lipofectamine, each, in totally 3 ml OPTI-MEM. After 4 h, the transfection mixture was replaced by OPTI-MEM þ 10% FCS. The siRNA sequences were: K1 gactggcagagtcctggttgt, K2 gtgggtctgtccttccctact, K3 gaccgtcctgagtggccatgt, K4 acgcc cttagaggtggctaca.
Semiquantitative RT-PCR Cells washed with PBS were lysed in 350 ml RLT buffer (RNAeasy minikit, Qiagen). RNA extraction was done according to the protocol of Qiagen. cDNA synthesis was performed with 0.25 mg of total RNA using the superscript2 cDNA synthesis kit (Invitrogen). RT-PCR was performed using the LightCycler-system and the LightCycler FastStart DNA Master Hybridization Probes kit (Roche Diagnostics). Primers for G6PD and KCNMA1 hybridization products were obtained from TIB MolBiol (Berlin, BRD). PCR primers were: KCNMA1: KCNMA1_s: cctggcctcctccatggt, KCNMA1_a: ttct gggcctccttcgtct, G6PD: G6ex7,8 R ttctgcatcacgtcccgga, G6ex6 S accactacctgggcaaggag. Hybridization probes were: KCNMA1: KCNMA1_fl: agcgtccgccagagcaagat, KCNMA1_lc: atgaagagg cccccgaagaaagt, G6PD: G6ex_FL: cagatggggccgaagatcctgtt, G6ex_LC: caaatctcagcaccatgaggttctgcac. PCR conditions were: activation: 10 min 951C PCR cycle: 5 s at 951C, annealing 5 s at 571C, elongation 15 s at 721C, 40 cycles. Raw data for KCNMA1 expression were corrected by comparing to the related G6PD controls. Then these corrected values were compared to each other to obtain relative expression.
Patch clamp experiments
Cell culture dishes were mounted on the stage of an inverted microscope (IM35, Carl Zeiss AG, Oberkochen, BRD) and kept at 371C. Patch clamp experiments were performed in the fast whole-cell and cell excised inside/out configuration. The patch pipettes had an input resistance of 2-4 MO when filled with a solution containing (mmol/l) KCl 30, K-gluconate 95, NaH 2 PO 4 1.2, Na 2 HPO 4 4.8, ethyleneglycol tetraacetate 1, CaCl 2 0.726, MgCl 2 1.034, D-glucose 5, adenosine triphosphate 1 (32 Cl). The pH was adjusted to 7.2, the Ca 2 þ activity was either 0.1 or 1 mmol/l. The access conductance was between 30 and 120 nS. In regular intervals, membrane voltages (V m ) were clamped in steps of 10 mV from À50 to þ 50 mV and whole-cell conductances were calculated according to Ohm's law. Currents (voltage clamp) and voltages (current clamp) were recorded using a patch clamp amplifier (EPC 7, List Medical Electronic, Darmstadt, Germany), the LIH1600 interface and PULSE software (HEKA) as well as Chart software (AD-Instruments). Data were analysed using PULSE and Origin software. In membrane patches containing several BK channels, channel activity was determined by multiplying single channel P o with the number of active channels in the membrane patch. NS1619, IBTX, paxillin and b-estradiol were from Sigma.
Statistical analysis
Statistical significance was verified in the Figures 2, 4 and 5 with an analysis of variance test using JMP-IN software (release 5.1, SAS Institute GmbH, Heidelberg, BRD). Statistical significance was assumed when Po0.05; n ¼ 3 for these figures. For all patch clamp experiments, Student's t-test P-values o0.05 were accepted to indicate statistical significance (*).
